Medications for Weight Reduction

Medical Clinics of North America

Volumn 95, Issue 5, 2011, Pages 989-1008

  Bray, George A ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Cannabinoid receptor antagonists; Glucagon like peptide analogues; Lipase inhibitor; Sympathomimetic drugs

Indexed keywords

AMFEBUTAMONE; AMFEPRAMONE; BENZPHETAMINE; CETILISTAT; EXENDIN 4; FLUOXETINE; LAMOTRIGINE; LORCASERIN; METFORMIN; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; PHENDIMETRAZINE; PHENTERMINE; PLACEBO; PRAMLINTIDE; RAFABEGRON; RIMONABANT; SEROTONIN 2C AGONIST; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; ZONISAMIDE;

ANXIETY; ASTHENIA; BODY MASS; CENTRAL NERVOUS SYSTEM; COMPARATIVE STUDY; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; ENERGY EXPENDITURE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPID ABSORPTION; META ANALYSIS (TOPIC); MOOD CHANGE; MORNING DOSAGE; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CLINICAL TRIALS AS TOPIC; HUMANS; OBESITY; OVERWEIGHT; WEIGHT LOSS;

EID: 80051735396     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2011.06.009     Document Type: Review

References (88)

1. World Health Organization Obesity: preventing and managing the global epidemic 1998, World Health Organization, Geneva (Switzerland).
2. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 1998, 6(Suppl 2):51S-209S.
3. Ogden C.L., Yanovski S.Z., Carroll M.D., et al. The epidemiology of obesity. Gastroenterology 2007, 132(6):2087-2102.
4. Bray G.A. The metabolic syndrome and obesity 2007, Humana Press, Totowa (NJ).
5. Padwal R., Li S.K., Lau D.C. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003, 27(12):1437-1446.
6. Shekelle P.G., Hardy M.L., Morton S.C., et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003, 289(12):1537-1545.
7. Li Z., Maglione M., Tu W., et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005, 142(7):532-546.
8. Bray G., Greenway F. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007, 59(2):151-184.
9. Bray G.A., Greenway F.L. Current and potential drugs for treatment of obesity. Endocr Rev 1999, 20(6):805-875.
10. Bray G.A., Ryan D.H. Drug treatment of the overweight patient. Gastroenterology 2007, 132(6):2239-2252.
11. Shekelle P.G., Morton S.C., Maglione M., et al. Pharmacological and surgical treatment of obesity. Evid Rep Technol Assess (Summ) 2004, (103):1-6.
12. Avenell A., Brown T.J., McGee M.A., et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet 2004, 7(4):293-316.
13. Smith I.G., Goulder M.A. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001, 50(6):505-512.
14. Apfelbaum M., Vague P., Ziegler O., et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999, 106(2):179-184.
15. James W.P., Astrup A., Finer N., et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group (Sibutramine Trial of Obesity Reduction and Maintenance). Lancet 2000, 356(9248):2119-2125.
16. Wirth A., Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001, 286(11):1331-1339.
17. McMahon F.G., Fujioka K., Singh B.N., et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000, 160(14):2185-2191.
18. Fujioka K., Seaton T.B., Rowe E., et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000, 2(3):175-187.
19. Berkowitz R.I., Wadden T.A., Tershakovec A.M., et al. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003, 289(14):1805-1812.
20. Godoy-Matos A., Carraro L., Vieira A., et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 2005, 90(3):1460-1465.
21. Berkowitz R.I., Fujioka K., Daniels S.R., et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006, 145(2):81-90.
22. Daniels S.R., Arnett D.K., Eckel R.H., et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 2005, 111(15):1999-2012.
23. Wadden T.A., Berkowitz R.I., Womble L.G., et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005, 353(20):2111-2120.
24. Sjostrom L., Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients: European Multicentre Orlistat Study Group. Lancet 1998, 352(9123):167-172.
25. Torgerson J.S., Hauptman J., Boldrin M.N., et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27(1):155-161.
26. Chanoine J.P., Hampl S., Jensen C., et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005, 293(23):2873-2883.
27. Hollander P.A., Elbein S.C., Hirsch I.B., et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998, 21(8):1288-1294.
28. Kelley D.E., Bray G.A., Pi-Sunyer F.X., et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002, 25(6):1033-1041.
29. Miles J.M., Leiter L., Hollander P., et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002, 25(7):1123-1128.
30. Heymsfield S.B., Segal K.R., Hauptman J., et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000, 160(9):1321-1326.
31. Zhi J., Mulligan T.E., Hauptman J.B. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999, 39(1):41-46.
32. Wadden T.A., Berkowitz R.I., Womble L.G., et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000, 8(6):431-437.
33. Lawton C.L., Wales J.K., Hill A.J., et al. Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. Obes Res 1995, 3(4):345-356.
34. Goldstein D.J., Rampey A.H., Roback P.J., et al. Efficacy and safety of long-term fluoxetine treatment of obesity: maximizing success. Obes Res 1995, 4(Suppl 3):481S-490S.
35. Gadde K.M., Parker C.B., Maner L.G., et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001, 9(9):544-551.
36. Jain A.K., Kaplan R.A., Gadde K.M., et al. Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002, 10(10):1049-1056.
37. Anderson J.W., Greenway F.L., Fujioka K., et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002, 10(7):633-641.
38. Astrup A., Toubro S. Topiramate: a new potential pharmacological treatment for obesity. Obes Res 2004, 12(Suppl):167S-173S.
39. Ben-Menachem E., Axelsen M., Johanson E.H., et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003, 11(4):556-562.
40. Bray G.A., Hollander P., Klein S., et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003, 11(6):722-733.
41. Wilding J., Van Gaal L., Rissanen A., et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004, 28(11):1399-1410.
42. Astrup A., Caterson I., Zelissen P., et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004, 12(10):1658-1669.
43. Gadde K.M., Franciscy D.M., Wagner H.R., et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003, 289(14):1820-1825.
44. Devinsky O., Vuong A., Hammer A., et al. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000, 54(4):973-975.
45. Merideth C.H. A single-center, double-blind, placebo-controlled evaluation of lamotrigine in the treatment of obesity in adults. J Clin Psychiatry 2006, 67(2):258-262.
46. Fontbonne A., Charles M.A., Juhan-Vague I., et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution: BIGPRO study group. Diabetes Care 1996, 19(9):920-926.
47. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346(6):393-403.
48. Ortega-Gonzalez C., Luna S., Hernandez L., et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90(3):1360-1365.
49. Riddle M.C., Drucker D.J. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006, 29(2):435-449.
50. Ratner R.E., Dickey R., Fineman M., et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 2004, 21(11):1204-1212.
51. Maggs D., Shen L., Strobel S., et al. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism 2003, 52(12):1638-1642.
52. Patriti A., Facchiano E., Sanna A., et al. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 2004, 14(6):840-848.
53. Small C.J., Bloom S.R. Gut hormones as peripheral anti-obesity targets. Curr Drug Targets CNS Neurol Disord 2004, 3(5):379-388.
54. Greenway S.E., Greenway F.L., Klein S. Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg 2002, 137(10):1109-1117.
55. Lugari R., Dei Cas A., Ugolotti D., et al. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res 2004, 36(2):111-115.
56. Szayna M., Doyle M.E., Betkey J.A., et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000, 141(6):1936-1941.
57. Gedulin B.R., Nikoulina S.E., Smith P.A., et al. Exenatide (exendin-4) improves insulin sensitivity and beta-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005, 146(4):2069-2076.
58. Rodriquez de Fonseca F., Navarro M., Alvarez E., et al. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 2000, 49(6):709-717.
59. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003, 27(3):313-318.
60. Edwards C.M., Stanley S.A., Davis R., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001, 281(1):E155-E161.
61. Fineman M.S., Shen L.Z., Taylor K., et al. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004, 20(5):411-417.
62. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28(5):1092-1100.
63. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28(5):1083-1091.
64. Buse J.B., Henry R.R., Han J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27(11):2628-2635.
65. Heine R.J., Van Gaal L.F., Johns D., et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143(8):559-569.
66. Van Gaal L.F., Rissanen A.M., Scheen A.J., et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365(9468):1389-1397.
67. Despres J.P., Golay A., Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353(20):2121-2134.
68. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA 2006, 295(7):761-775.
69. Scheen A.J., Finer N., Hollander P., et al. RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 2006, 368:1660-1672.
70. Parker E., Van Heek M., Stamford A. Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status. Eur J Pharmacol 2002, 440(2/3):173-187.
71. Erondu N., Gantz I., Musser B., et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006, 4(4):275-282.
72. Erondu N., Wadden T., Gantz I., et al. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring) 2007, 15(4):895-905.
73. Gibson W.T., Ebersole B.J., Bhattacharyya S., et al. Mutational analysis of the serotonin receptor 5-HT2C in severe early-onset human obesity. Can J Physiol Pharmacol 2004, 82(6):426-429.
74. Nilsson B.M. 5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents. J Med Chem 2006, 49(14):4023-4034.
75. Cangiano C., Ceci F., Cascino A., et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr 1992, 56(5):863-867.
76. Cangiano C., Laviano A., Del Ben M., et al. Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin-dependent diabetic patients. Int J Obes Relat Metab Disord 1998, 22(7):648-654.
77. Rogers P.J., Blundell J.E. Effect of anorexic drugs on food intake and the micro-structure of eating in human subjects. Psychopharmacology (Berl) 1979, 66(2):159-165.
78. Foltin R.W., Haney M., Comer S.D., et al. Effect of fenfluramine on food intake, mood, and performance of humans living in a residential laboratory. Physiol Behav 1996, 59(2):295-305.
79. Drent M.L., Zelissen P.M., Koppeschaar H.P., et al. The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks. Int J Obes Relat Metab Disord 1995, 19(5):299-304.
80. Walsh A.E., Smith K.A., Oldman A.D., et al. m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology (Berl) 1994, 116:120-122.
81. Boeles S., Williams C., Campling G.M., et al. Sumatriptan decreases food intake and increases plasma growth hormone in healthy women. Psychopharmacology (Berl) 1997, 129(2):179-182.
82. Smith S.R., Prosser W., Donahue D., et al. APD356, an orally-active selective 5-HT2C agonist reduces body weight in obese men and women. Diabetes Metab 2006, 55(Suppl 1):A80.
83. Dunk C., Enunwa M., De La Monte S., et al. Increased fecal fat excretion in normal volunteers treated with lipase inhibitor ATL-962. Int J Obes Relat Metab Disord 2002, 26(Suppl):S135.
84. Kopelman P., Bryson A., Hickling R., et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 2007, 31(3):494-499.
85. Weintraub M. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992, 51(5):581-585.
86. Stafford R.S., Radley D.C. National trends in antiobesity medication use. Arch Intern Med 2003, 163(9):1046-1050.
87. Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337(9):581-588.
88. Redman L.M., de Jonge L., Fang X., et al. Lack of an effect of a novel beta-3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study. J Clin Endocrinol Metab 2007, 92(2):527-531.